140 related articles for article (PubMed ID: 6133854)
1. Problems of compliance in the outpatient treatment of schizophrenia.
Kane JM
J Clin Psychiatry; 1983 Jun; 44(6 Pt 2):3-6. PubMed ID: 6133854
[TBL] [Abstract][Full Text] [Related]
2. Overview of partial compliance.
Marder SR
J Clin Psychiatry; 2003; 64 Suppl 16():3-9. PubMed ID: 14680412
[TBL] [Abstract][Full Text] [Related]
3. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
[TBL] [Abstract][Full Text] [Related]
4. Dose response of prophylactic antipsychotics.
Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
[TBL] [Abstract][Full Text] [Related]
5. Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs.
Gaebel W
Int Clin Psychopharmacol; 1997 Feb; 12 Suppl 1():S37-42. PubMed ID: 9179642
[TBL] [Abstract][Full Text] [Related]
6. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
Agid O; Foussias G; Remington G
Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707
[TBL] [Abstract][Full Text] [Related]
7. [Compliance problems in treatment of schizophrenic patients].
Barnas C; Hummer M; Fleischhacker WW
Wien Med Wochenschr; 1998; 148(11-12):281-3. PubMed ID: 9746971
[TBL] [Abstract][Full Text] [Related]
8. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
Misdrahi D; Llorca PM; Lançon C; Bayle FJ
Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
[TBL] [Abstract][Full Text] [Related]
9. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
[TBL] [Abstract][Full Text] [Related]
10. Substance abuse and the management of medication nonadherence in schizophrenia.
Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
[TBL] [Abstract][Full Text] [Related]
11. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
Glazer WM; Ereshefsky L
J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
[TBL] [Abstract][Full Text] [Related]
12. Strategies for dosing and switching antipsychotics for optimal clinical management.
Buckley PF; Correll CU
J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
[TBL] [Abstract][Full Text] [Related]
13. Management strategies for the treatment of schizophrenia.
Kane JM
J Clin Psychiatry; 1999; 60 Suppl 12():13-7. PubMed ID: 10372604
[TBL] [Abstract][Full Text] [Related]
14. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
Bhanji NH; Chouinard G; Margolese HC
Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
[TBL] [Abstract][Full Text] [Related]
15. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
Turner MS; Stewart DW
J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic long-acting injections: mind the gap.
Patel MX; Taylor M; David AS
Br J Psychiatry Suppl; 2009 Nov; 52():S1-4. PubMed ID: 19880911
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic alliance, a stake in schizophrenia].
Charpentier A; Goudemand M; Thomas P
Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
[TBL] [Abstract][Full Text] [Related]
18. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to make the decision to resort to an APAP)].
Chéreau I; Gorwood P; Mouchabac S
Encephale; 2009 Jan; Suppl 3():S97-100. PubMed ID: 19268186
[No Abstract] [Full Text] [Related]
19. [Adherence to antipsychotic medication in schizophrenia patients].
Baloush-Kleinman V; Poyurovsky M; Koren D; Schneidman M; Weizman A; Shnitt D
Harefuah; 2002 Dec; 141(12):1042-9, 1090. PubMed ID: 12534202
[TBL] [Abstract][Full Text] [Related]
20. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
Johnson DA
J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
